Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives

Alzheimer's disease (AD) is the most common type of dementia. Monoclonal antibodies (MABs) serve as a promising therapeutic approach for AD by selectively targeting key pathogenic factors, such as amyloid-β (Aβ) peptide, tau protein, and neuroinflammation. Specifically, based on their efficacy in removing Aβ plaques from the brains of patients with AD, the U.S. Food and Drug Administration has approved three anti-amyloid MABs, aducanumab (Aduhelm®), lecanemab (Leqembi®), and donanemab (Kisunla™). Notably, lecanemab received traditional approval after demonstrating clinical benefit, supporting the Aβ cascade hypothesis. These MABs targeting Aβ are categorized based on their affinity to diverse conformational…

• NR
  National Research Foundation
• KH
  Korea Health Industry Development Institute

  Award: RS-2023-KH138733
• NR
  National Research Foundation of Korea

  Awards: 2022R1A6A3A13053190, RS-2023-00240010, RS-2024-00450135, RS-2023-00212388, RS-2023-00273557, NRF-2022R1A6A3A13053190